Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 4(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04765995Phase 1Completed

Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of of HZBio1 in Healthy Subjects

Role: lead

NCT06250400Phase 4Unknown

Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU)

Role: lead

NCT04982380Phase 4Unknown

Efficacy and Safety of Bifidobacterium Quadruple Live Tablets in Patients With T2DM and Constipation

Role: collaborator

NCT04034641Phase 4Unknown

Effect of Probiotics on Helicobacter Pylori Eradication

Role: lead

All 4 trials loaded